team-David-Chao

David Chao PhD

Chief Administrative Officer

Dr. David Chao, PhD, is Chief Administrative Officer of Centessa Pharmaceuticals. Most recently, Dave held the roles of President and Chief Executive Officer of Stowers Institute for Medical Research and President and Chief Executive Officer of BioMed Valley Discoveries.

Dave was also the President at The Graduate School of the Stowers Institute for Medical Research from 2010–2018 and a member of the Board of Directors for the American Century Companies from 2012-2020.

Earlier in his career, Dave was Head of Strategic Alliances Global Operations at the Novartis Institutes of BioMedical Research and a consultant in McKinsey & Company’s Pharmaceutical and Medical Product Practice.

Dave holds a PhD in Biology from M.I.T. and a combined AM and AB in Biology from Harvard University.

Scroll to Top
;
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B